Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

Journal Articles

Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma

Changying Jiang, PhD, Shaojun Zhang, PhD, Shengjian Huang, PhD, Yang Liu, MD, Rongjia Zhang, Angela Leeming, Joseph Mitchell McIntosh, William Lee, Krystle Nomie, PhD, Linghua Wang, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 3974.

https://doi.org/10.1182/blood-2019-128810

Published: 2019

Journal Articles

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Myoung Woo Lee, Hye Jin Kim, Dae Seong Kim, Meong Hi Son, MD, Soo Hyun Lee, MD, Hye Lim Jung, MD, Keon Hee Yoo, MD, Ki Woong Sung, MD, Hong Hoe Koo, MD

Blood (2011) 118 (21): 4879.

https://doi.org/10.1182/blood.V118.21.4879.4879

Published: 2011

Journal Articles

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Salvia Jain, MD, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Jennifer Amengual, M.D., Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2725.

https://doi.org/10.1182/blood.V118.21.2725.2725

Published: 2011

Journal Articles

Finding of 8 New Therapeutic Agents by the Use of New High-Throughput Drug Screening Methods Established by the Nhlbi Sicke Cell Disease Reference Laboratory.

Toshio Asakura, MD, PhD, Osheiza Abdulmalik, DVM, Efe Iyamu, PhD, Qiukan Chen, MD, Jisheng Yang, Carlo Brugnara, MD, Greg Evans, PhD

Blood (2004) 104 (11): 3751.

https://doi.org/10.1182/blood.V104.11.3751.3751

Published: 2004

NARROW

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Finding of 8 New Therapeutic Agents by the Use of New High-Throughput Drug Screening Methods Established by the Nhlbi Sicke Cell Disease Reference Laboratory.

Email alerts

ASH Publications

American Society of Hematology

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Finding of 8 New Therapeutic Agents by the Use of New High-Throughput Drug Screening Methods Established by the Nhlbi Sicke Cell Disease Reference Laboratory.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only